after joining the study, you will undergo medical examinations, blood tests, and imaging studies to document the current status of the disease.

the purpose is to create a reference point for later comparisons and to confirm eligibility for the trial.

on day 1 of the cycle, you will receive ubamatamab by intravenous administration.

in the same session, the chemotherapy drugs carboplatin and paclitaxel are also given by intravenous administration.

additionally, the anti‑angiogenic agent bevacizumab is infused intravenously.

if required, the growth‑factor support drug filgrastim may be administered to help maintain blood cell counts.

for the first four weeks after the initial infusion, you will be closely observed for any side effects that could limit the dose.

regular visits, blood tests, and clinical evaluations are performed to detect adverse events early.

treatment cycles are repeated according to the study schedule, typically every three weeks.

each cycle includes the same set of intravenous infusions: ubamatamab, carboplatin, paclitaxel, and bevacizumab.

the number of cycles continues until the planned course is completed, disease progression occurs, or toxicity requires discontinuation.

after completing three cycles, imaging studies are performed to assess tumor response.

the evaluation determines whether the disease shows complete response, partial response, stable disease, or progression.

if the response evaluation indicates, a surgical procedure may be offered after the third cycle to remove remaining tumor tissue.

the decision for surgery is based on the individual clinical situation.

if the disease does not progress and side effects remain manageable, treatment continues with additional cycles until the protocol‑defined end point.

treatment may be stopped earlier if disease progression or unacceptable toxicity occurs.

after the last infusion, you will have scheduled follow‑up visits for clinical assessment and imaging.

these visits monitor long‑term outcomes such as progression‑free survival and overall survival.